We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+11.82%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$252M
AUM Growth
-$117M
(-32%)
Cap. Flow
-$61.6M
Cap. Flow
% of AUM
-24.44%
Top 10 Holdings %
Top 10 Hldgs %
67.87%
Holding
57
New
9
Increased
3
Reduced
13
Closed
18
Avg Time Held Equity + Options
3.1
quarters
Top 10 Avg Time Held Equity + Options
0.9
quarters
Top 20 Avg Time Held Equity + Options
1.9
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
1.1
quarters
Top 20 Avg Time Held Equity only
2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$23.6M |
| 2 |
Maximus
MMS
|
+$13.9M |
| 3 |
Annexon
ANNX
|
+$8.5M |
| 4 |
Relay Therapeutics
RLAY
|
+$7.07M |
| 5 |
IDEAYA Biosciences
IDYA
|
+$4.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teleflex
TFX
|
+$16.8M |
| 2 |
Labcorp
LH
|
+$16M |
| 3 |
Smith & Nephew
SNN
|
+$14.4M |
| 4 |
Organon & Co
OGN
|
+$12.6M |
| 5 |
GSK
GSK
|
+$12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.37% |
| 2 | Miscellaneous | 11.54% |
| 3 | Industrials | 5.73% |
| 4 | Consumer Staples | 4.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Labcorp
LH
$25.4B
| $38.7M | 15.36% |
173,293
-72,609
| -30% | -$16M |
2023 Q2
5 quarters
|
|
2
PUT
Intuitive Surgical
ISRG
$149B
| $29M | 11.49% |
+59,000
| New | +$27.5M |
2024 Q3
0 quarters
|
|
|
3
Teva Pharmaceutical Industries Limited
TEVA
$48.1B
| $24.3M | 9.64% |
+1,349,274
| New | +$23.6M |
2024 Q3
0 quarters
|
|
|
4
Maximus
MMS
$3.04B
| $14.5M | 5.73% |
+155,142
| New | +$13.9M |
2024 Q3
0 quarters
|
|
5
Zimmer Biomet
ZBH
$17.6B
| $13.8M | 5.46% |
127,511
-27,793
| -18% | -$3.03M |
2023 Q3
4 quarters
|
|
6
DELISTED
Vaxart
VXRT
| $11.6M | 4.58% |
13,608,244
-1,156,747
| -8% | -$884K |
2024 Q2
1 quarter
|
|
7
Kenvue
KVUE
$34.1B
| $11M | 4.35% |
474,741
-10,259
| -2% | -$213K |
2024 Q2
1 quarter
|
|
|
8
Teleflex
TFX
$5.27B
| $9.71M | 3.85% |
39,272
-71,806
| -65% | -$16.8M |
2023 Q3
4 quarters
|
|
9
Tyra Biosciences
TYRA
$1.28B
| $9.42M | 3.74% |
400,870
-199,424
| -33% | -$4.19M |
2024 Q1
2 quarters
|
|
10
Disc Medicine
IRON
$2.17B
| $9.24M | 3.66% |
187,941
-4,059
| -2% | -$191K |
2024 Q2
1 quarter
|
|
11
Cigna
CI
$74.7B
| $9.18M | 3.64% |
26,503
-283
| -1% | -$97.4K |
2020 Q3
16 quarters
|
|
|
12
Annexon
ANNX
$726M
| $8.48M | 3.36% |
+1,433,155
| New | +$8.5M |
2024 Q3
0 quarters
|
|
13
Biodesix
BDSX
$264M
| $7.72M | 3.06% |
216,926
-467
| -0.2% | -$16.1K |
2024 Q2
1 quarter
|
|
|
14
Relay Therapeutics
RLAY
$3.8B
| $6.7M | 2.66% |
+945,839
| New | +$7.07M |
2024 Q3
0 quarters
|
|
15
Erasca
ERAS
$5.17B
| $6.06M | 2.4% |
2,219,186
-655,350
| -23% | -$1.85M |
2024 Q1
2 quarters
|
|
16
Compass Pathways
CMPS
$1.54B
| $5.76M | 2.29% |
914,639
+621,222
| +212% | +$4.38M |
2024 Q2
1 quarter
|
|
17
DELISTED
Astria Therapeutics
ATXS
| $5.56M | 2.2% |
504,887
-5,380
| -1% | -$59.8K |
2024 Q1
2 quarters
|
|
18
PMV Pharmaceuticals
PMVP
$72.2M
| $4.79M | 1.9% |
3,214,239
+505,831
| +19% | +$782K |
2024 Q2
1 quarter
|
|
19
DELISTED
Ventyx Biosciences
VTYX
| $4.3M | 1.7% |
1,971,948
+1,193,024
| +153% | +$2.74M |
2024 Q1
2 quarters
|
|
|
20
IDEAYA Biosciences
IDYA
$3.31B
| $3.9M | 1.55% |
+123,000
| New | +$4.66M |
2024 Q3
0 quarters
|
|
21
Artivion
AORT
$1.04B
| $3.23M | 1.28% |
+121,178
| New | +$3.15M |
2024 Q3
0 quarters
|
|
22
DELISTED
CARGO Therapeutics
CRGX
| $3.21M | 1.27% |
+173,860
| New | +$3.11M |
2024 Q3
0 quarters
|
|
23
Context Therapeutics
CNTX
$25.3M
| $2.6M | 1.03% |
1,328,352
| – | – |
2024 Q2
1 quarter
|
|
24
Enanta Pharmaceuticals
ENTA
$336M
| $1.83M | 0.73% |
177,004
| – | – |
2024 Q1
2 quarters
|
|
25
Nuvation Bio
NUVB
$1.66B
| $1.53M | 0.61% |
668,115
| – | – |
2024 Q1
2 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q3 2024 Portfolio in Review
As of Q3 2024, Sio Capital Management held 57 positions worth $252M, down 32% from $370M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Sio Capital Management withdrew a net $61.6M in Q3 2024, closing 18 positions and reducing 13 holdings. Its most notable exit was Smith & Nephew, an estimated $14.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 69% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, Sio Capital Management opened a new position in Teva Pharmaceutical Industries Limited worth $24.3M.
- Sio Capital Management's largest Q3 2024 buy was Teva Pharmaceutical Industries Limited: 1,349,274 shares worth $24.3M.
- Sio Capital Management added most to Compass Pathways in Q3 2024, an estimated $4.38M increase.
- Sio Capital Management's biggest Q3 2024 reduction was Teleflex, cutting an estimated $16.8M.
- Sio Capital Management fully exited Smith & Nephew in Q3 2024, selling an estimated $14.4M.
- Sio Capital Management's ten largest holdings make up 68% of its $252M portfolio in Q3 2024.
- Sio Capital Management opened 9 new positions and closed 18 in Q3 2024.
- Sio Capital Management's portfolio value fell 32% quarter-over-quarter to $252M.
Based on Sio Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.